Therefore, the inactivation of ALDH-2 in the STZ group substantially supports the cardio-toxic phenotype of hyperglycemia and improved activity of this redox-sensitive enzyme by a high dose SGLT2i therapy clearly points to cardio-protective and anti-oxidant properties of this drug. The gene discussed is ALDH2; the disease is Hyperglycemia.